Actively Recruiting
An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers.
Led by Pharus Taiwan, Inc. · Updated on 2025-09-19
1340
Participants Needed
1
Research Sites
138 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to observe whether miRNA and DNA methylation collected through liquid biopsy can serve as a biomarker for evaluating lung cancer.
CONDITIONS
Official Title
An Observational Study on the Assessment of Lung Cancer Using Liquid Biopsy for Collecting miRNA Expression Profile and DNA Methylation Biomarkers.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female or male participants at least 18 years of age
- Participants in the test group must have identified lung nodules or masses through low-dose computed tomography (LDCT)CT scan, and have a scheduled medical operation, which is not limited to surgical excision. Control group participants should have no significant findings in LDCT/CT scan displaying either no nodules, or nodules smaller than 6mm were assessed by investigators without clinically significant justification, through an axial resolution of 3 mm or less, within 2 months prior to their enrollment in the study.
- Participants in the test group should be treatment naïve.
- Ability to complete a questionnaire, comprehend and comply with the requirements of the study
- Written informed consent, and authorization to use and disclose health information
You will not qualify if you...
- Has any history of cancer diagnosis
- Has received a blood transfusion (except for autologous blood transfusion) within the first two months prior to participating the trial
- Is participating in a clinical trial (the non-intervention trial will be accepted)
- Has taken gene therapy within one year prior to participating the trial
- Has any vaccinations within 3 months prior to blood sample collection
- Is currently pregnant
- Has any severe acute or uncontrolled chronic lung disease such as pneumonia, lung abscess, acute exacerbation of COPD or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of Study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this Study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Pharus Taiwan, Inc.
Hsinchu, Taiwan
Actively Recruiting
Research Team
D
Director of Data Science
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here